Kidswell Bio Corporation (4584)

Market cap
¥12B
P/E ratio
KidsWell Bio develops biosimilar drugs and regenerative medicine treatments using SQ-SHED stem cells from baby teeth for pharmaceutical partners and rare disease patients.
Period EndOperating expenses (Million JPY)YoY (%)
Mar 31, 20251,612-32.12%
Mar 31, 20242,375+14.37%
Mar 31, 20232,077+7.15%
Mar 31, 20221,938+4.95%
Mar 31, 20211,847+16.44%
Mar 31, 20201,586+12.09%
Mar 31, 20191,415-8.76%
Mar 31, 20181,551-17.36%
Mar 31, 20171,877+26.75%
Mar 31, 20161,480+48.32%
Mar 31, 2015998
AI Chat